Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Ipidacrine→

Ipidacrine PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
62732-44-9
Molecular formula
C12H16N2
Molecular weight
188.27 g/mol
Drug class
Reversible acetylcholinesterase inhibitorpotassium-channel blocker and cholinergic neuromodulator
Mechanism of action
Reversibly inhibits acetylcholinesterase, increasing acetylcholine at central and peripheral cholinergic synapses. It also blocks voltage-gated potassium channels, prolonging neuronal action potentials and enhancing presynaptic calcium entry and neurotransmitter release.
Indications / reported uses
  • Symptomatic treatment of acquired mononeuropathies and polyneuropathies in adults.
  • Adjunctive symptomatic treatment of myasthenia gravis and selected bulbar dysfunction during recovery after brainstem ischaemic stroke.
  • Symptomatic treatment of mild-to-moderately severe Alzheimer’s disease and intestinal atony, where authorised under the revised European product information. Other previously listed uses were restricted or removed following the EMA review in September 2026.

Sources: https://www.ema.europa.eu/en/medicines/human/referrals/ipidacrine-containing-medicinal-products · https://www.ema.europa.eu/en/documents/referral/ipidacrine-containing-medicinal-products-article-31-referral-ema-concludes-review-ipidacrine-containing-medicines_en.pdf

View request basketPrefer email? [email protected]
PDE / ADE derivationOEL derivationOEB / OHC bandingRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Reversible acetylcholinesterase inhibitor; potassium-channel blocker and cholinergic neuromodulator

Mechanism of action

Reversibly inhibits acetylcholinesterase, increasing acetylcholine at central and peripheral cholinergic synapses. It also blocks voltage-gated potassium channels, prolonging neuronal action potentials and enhancing presynaptic calcium entry and neurotransmitter release.

General use cases

  • Symptomatic treatment of acquired mononeuropathies and polyneuropathies in adults.
  • Adjunctive symptomatic treatment of myasthenia gravis and selected bulbar dysfunction during recovery after brainstem ischaemic stroke.
  • Symptomatic treatment of mild-to-moderately severe Alzheimer’s disease and intestinal atony, where authorised under the revised European product information. Other previously listed uses were restricted or removed following the EMA review in September 2026.

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

Assessment scope

Project-specific PDE/ADE and OEL/OEB support

Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.

  • PDE/ADE: critical effects, point of departure and justified adjustment factors.
  • OEL: inhalation hazards, exposure duration and workplace conditions.
  • OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
  • Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope

PDE/ADE and OEL/OEB assessment

ReguSight provides project-specific support for Ipidacrine PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Ipidacrine Permitted Daily Exposure (PDE) report (the Ipidacrine PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Ipidacrine Occupational Exposure Limit (OEL) report (the Ipidacrine OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.